Informations

Key Highlights Q1: Could you briefly introduce the current research landscape in cancer immunotherapy, particularly in novel immune checkpoint pathways, and why you chose this area as your focus? Dr.…

Oncology Frontier: The 2024 Elite Lung Cancer Symposium has successfully concluded. As the conference chair, could you share the key highlights of this event? Dr. Cheng Huang: The 2024 Elite…

The “Northern Breast Cancer Salon Annual Progress Review” was held in Beijing from January 3 to 5, 2025, providing a comprehensive overview of the latest developments in the diagnosis, treatment, and research of breast cancer over the past year. Dr. Shusen Wang from the Sun Yat-sen University Cancer Center presented a summary of the advances…

In recent years, immunotherapy drugs, particularly PD-1/PD-L1 inhibitors, have gradually expanded from being used in later-line treatments to frontline therapy for non-small cell lung cancer (NSCLC). Perioperative immunotherapy has become a major focus in the field, with numerous breakthroughs reshaping the treatment landscape for operable NSCLC patients. However, challenges remain in patient selection, treatment regimens,…

As 2024 concludes, the year has left us with significant milestones and breakthroughs in oncology. Oncology Frontier invited Dr. Yongmei Yin from Jiangsu Cancer Hospital to summarize the year’s advancements in HER2-positive breast cancer research, highlighting the clinical transformations brought by innovative therapies.

Oncology Frontier: With the progress in the precise diagnosis of lung cancer, many rare/rare gene mutations have been discovered. First, could you briefly introduce the current hottest rare targets? Dr.…